Lymphatic Targeting - Milk Exosomes

Harness the evolved functionality of exosomes to develop novel therapeutics

TRIAL PHASE
PROGRAMDISCOVERYLEAD OPTIMIZATIONIND-ENABLINGPHASE 1PHASE 2PHASE 3 / PIVOTAL
Lymphatic Targeting - Milk Exosomes
Lymphatic Targeting - Milk Exosomes
Phase: DISCOVERY
Developing milk exosomes to leverage local GI-immune interactions for oral administration of nucleic acids and other biologics

PureTech’s novel milk exosome-based technology may be uniquely positioned to facilitate the oral administration of complex payloads such as nucleic acids, peptides, and small molecules, by harnessing our growing understanding of the biology at the gut-immune interface. Milk exosomes represent a versatile engineerable platform to potentially resolve the long-standing challenge of oral bioavailability of macromolecules and complex small molecules. This technology is based on the research of Professor Ramesh Gupta at University of Louisville, and is exclusively licensed to PureTech. 

We are advancing a broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD), multiple sclerosis (MS) and various other neuroinflammatory diseases. We are also developing associated clinical monitors and measurement-based care applications. Our lead, patented technology platform is exclusively licensed from the lab of Dr. Adam Gazzaley at the University of California, San Francisco (UCSF), and augmented by proprietary adaptive algorithms developed by our team.

  • Our Approach
    • Exosomes, which are composed of a multitude of components spanning lipids, proteins and nucleic acids, have been recognized as key players in intercellular communication and the transport of macromolecules between cells and tissues. Mammalian cell-derived exosomes have attractive potential as vehicles for the administration of a variety of drug payloads, especially nucleic acids, since their natural composition will likely provide superior tolerability over the variety of synthetic polymer-based approaches that are being used and tested in the clinic. However, most sources of mammalian exosomes are not suitable or viable as vehicles for oral administration of therapeutics due to their lack of stability under the harsh physiologic conditions associated with transit through the gastrointestinal tract.
    • The milk-derived exosomes that form the basis for PureTech’s technology have evolved naturally and specifically to accomplish the task of oral transport of complex biological molecules through this environment.
  • Intellectual Property
    • PureTech has broad intellectual property coverage for this platform technology, currently owning or having exclusive rights to twenty (20) patent applications in ten (10) families of patent filings that are licensed from 3P Biotechnologies and the University of Nebraska, which intellectual property is directed to compositions of matter, methods of use, and methods of treatment that cover classes of therapeutics as well as the broad platform technologies.
  • Collaborations
    • PureTech is continuing to build on the expertise developed for isolating milk exosomes and potentially expand the scope of complex payloads that might leverage its current approach for targeting of biologic payloads to the lymphatics. Building on these advances, in July 2018, PureTech Health announced a multiyear collaboration with Roche to advance this technology for the oral administration of Roche’s LNA antisense oligonucleotide platform. Under the terms of the agreement, PureTech will receive up to $36 million, including upfront payments, research support and early preclinical milestones. PureTech is also eligible to receive development milestone payments of over $1 billion, in addition to sales milestones and royalties. PureTech retains the rights to other applications spanning all complex small molecules, peptide/proteins, and nucleic acid-based therapeutics (such as mRNA, siRNA, and other non-LNA antisense oligonucleotide-based approaches).

PureTech is continuing to build on the expertise developed for isolating milk exosomes and potentially expand the scope of complex payloads that might leverage its current approach for targeting of biologic payloads to the lymphatics.